Ganitumab, identified by the CAS number 905703-97-1, is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor, which plays a crucial role in regulating immune responses. This therapeutic agent is primarily investigated for its potential in treating various types of cancers by enhancing the immune system's ability to recognize and attack tumor cells. Ganitumab is designed to inhibit the interaction between PD-1 and its ligands, thereby promoting T-cell activation and proliferation. Its structure consists of human IgG1 isotype, which contributes to its stability and efficacy. The drug is typically administered via intravenous infusion, and its pharmacokinetics can be influenced by factors such as dosage, patient-specific characteristics, and the presence of other medications. Clinical trials have been conducted to evaluate its safety, tolerability, and effectiveness in combination with other therapies. As with many monoclonal antibodies, potential side effects may include infusion-related reactions, immune-related adverse events, and other complications associated with immune modulation.

Ganitumab

905703-97-1: Ganitumab, identified by the CAS number 905703-97-1, is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor, which plays a crucial role in regulating immune responses. This therapeutic agent is primarily investigated for its potential in treating various types of cancers by enhancing the immune system's ability to recognize and attack tumor cells. Ganitumab is designed to inhibit the interaction between PD-1 and its ligands, thereby promoting T-cell activation and proliferation. Its structure consists of human IgG1 isotype, which contributes to its stability and efficacy. The drug is typically administered via intravenous infusion, and its pharmacokinetics can be influenced by factors such as dosage, patient-specific characteristics, and the presence of other medications. Clinical trials have been conducted to evaluate its safety, tolerability, and effectiveness in combination with other therapies. As with many monoclonal antibodies, potential side effects may include infusion-related reactions, immune-related adverse events, and other complications associated with immune modulation.

<p>Ganitumab (AMG 479) is a potent monoclonal antibody targeting IGF1R with 0.22 nM affinity; used in cancer research.</p>

<p>Anti-Human IGF1R Monoclonal Antibody</p>

CAS 905703-97-1

Ganitumab

Ganitumab

Ref: TM-T76810

Ganitumab

Ref: 3D-CLA1136